Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau30 enrolled

Overview

The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.

Design, Settings, and Participants. A randomised, double-blind, placebo-controlled trial with MDD patients allocated to two treatment arms: citalopram + pindolol versus citalopram + placebo. Participants: outpatients with a depressive episode (DSM-IV criteria) were selected from a general hospital.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Major Depressive Disorder Antidepressant Treatment Response

Interventions

PindololDRUG

Pill orally administered. 15 mg/day t.i.d.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a depressive episode * HDRS score \> 18 * Written informed consent Exclusion Criteria: * suicidal risk \> 3 * severe organic illness * other psychotropic drugs

Locations (1)

Outpatients Service of Psychiatry Department. Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, Spain

Outcomes

Primary Outcomes

Scores on Hamilton Depression Rating Scale

Time frame: 8 time points through 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.